期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阴茎勃起功能障碍的药物治疗进展 被引量：2

暂未订购
导出
摘要 阴茎勃起功能障碍(ED)在选择药物治疗之前,指导病人去除引起勃起功能障碍的各种诱因及危险因素十分重要,因为许多诱因和危险因素是可以克服的,如药物因素、吸烟、酗酒以及改善夫妻感情等.同时,也要加强原发疾病的治疗[1],如糖尿病、高血压、高血脂、内分泌疾病等.
作者 张元芳
机构地区 复旦大学附属华山医院泌尿外科
出处 《中国男科学杂志》 CAS CSCD 2004年第6期67-70,共4页 Chinese Journal of Andrology
关键词 阴茎勃起功能障碍 药物治疗 ED 原发疾病
分类号 R698.1 [医药卫生—泌尿科学]
  • 相关文献

参考文献14

  • 1Rajagopalan P, Mazzu A, Xia C, et al. Effect of highfat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodi -esterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43(3): 260-167
  • 2Hellstrom WJG, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction:efficacy and safety in a randomized,double-blind, placebo-conntrolled trial. J Anisozymes. Drol 2002; 23(6): 763-771
  • 3Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 Mar; 26(3): 77
  • 4Chung AT, Strauss JD, Murpny R, A. et al. Sildenafil.A type 5 cGMP phodiesterase inhibitor. Specifically amplifies endogenous cGMP dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro [J]. J Urol 1998; 160(1): 257-261
  • 5Weiske W H. Invasive diagnosis and therapy arethey still reasonable in the age of sildenafil. Andrology 1999; 31:95
  • 6Patterson B, Bedding A, Jewell H, et al. Dosenormalized pharmacokinetics of singledose tadalafil (IC351) in healthy volunteers. Int J Impot Res 2001; 13: S63.Abstract 14
  • 7Brock G, McMahon C, Chen K, et al. Efficacy and safety of tadalafei for the treatment of erectial dysfunction:Results of integrated analyses. J Urol 2002; 168:1332-1336
  • 8Fulgham P F, Cochran J S, Denman J L, et al. Disappointing initial results with transurethral alorostadil for erectile dysfunction in a urology practice setting. J Urol1998; 160(6): 2041-2046
  • 9Jardin A. Evaluation and treatment of ererctile dysfunction. 1st International consultation on erectile dysfunction,Paris, 1999; 1-3
  • 10Morales A, Gingell C, Collins M, et al. Clinical safety of sildenafil citrate(VIAGRA) in treatment of erectile dysfunction. Int J Impot Res 1998; 10(2): 69-73, discussion 73-74

二级参考文献11

  • 1Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences[J]. BJU Int, 1999, 84(1): 50-56.
  • 2Nehra A, Kulaksizoglu H. Global perspectives and controversies in the epidemiology of male erectile dysfunction [J]. Cuur Opin Urol, 2002, 12(6): 493-496.
  • 3Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial [J]. J Androl, 2002, 23(6) :763-771.
  • 4Donatucci C, Pommerville P, Niederberger C, et al. Vardenafil improved patient satisfaction with erection hardness, orgasmic function, and sexual experience in men with erectile dysfunction [J]. J Urol, 2003, 169(Supp14): 246.
  • 5Valiquette L, Hellstrom W, Gittelman M. Vardenafil provides reliable efficacy over time in men with erectile dysfunction [J]. Int J Impot Res, 2002, 14(Suppl 3): S88.
  • 6Stief C, Porst H, Saenz de Tejada Ⅰ, et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erecitle dysfunction[J]. Int J Clin Pract, 2004, 58 (3): 230- 239.
  • 7Padm a-Nathan H, Eardley Ⅰ, Collins O, et al. Vardenafil restores normal functioning to men with erectile dysfunction [J]. J Urol,2002, 167(4 Suppl): 177.
  • 8Goldstein Ⅰ, Young JM, Fishcher J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind pla cebo-controlled fixed-dose study [J]. Diabetes Care, 2003, 26 (3): 777-783.
  • 9Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first athome clinical trail[J]. Int J Impot Res, 2001 , 13 (4): 192-199.
  • 10Kloner RA, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction: an analysis of five placebo-controlled clinical trials [J]. Pharmacotherapy, 2002, 22 (10):1371.

共引文献9

同被引文献9

  • 1Rosen RC,Cappelleri JC,Smith MD,et al. Development and evaluation of an abridged,5-item version of the International Index of Erectile Function(IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res, 1999,11:319-326.
  • 2McCullough A, Woo K, Telegrafi S,et al. Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP. Int J Impot Res,2002,14:462-465.
  • 3Atiemo HO,Szostak MJ,Sklar GN.Salvage of sildenafil failures referred from primary care physicians.J Urol 2003; 170:2356-2358
  • 4Padma-Nathan H.The current state of care for erectile dysfunction.Contemp Urol 2000; 1(suppl); 4-11
  • 5Trummer H.Oral therapy of erectile dysfuntion.Wien Med Wochenschr 2000; 150(1-2):11-13
  • 6Rosen RC,Seidman SN,Menza MA,et al.Quality of life,mood,and sexual function:a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms.IntJImpotRes 2004; 16(4):334-340
  • 7Diamond LE,Earle DC,Garcia WD.Co-administration of low doses of intranasal PT-141,a melanocortin receptor agonist,and sildenafil to men with erectile dysfunction results in an enhanced erectile response.Urology 2005; 65(4):755-759
  • 8郭应禄,朱积川,潘天明,曹坚,江鱼,王益鑫,姚德鸿,胡礼泉.口服西地那非治疗勃起功能障碍疗效和安全性的临床研究[J].中华泌尿外科杂志,2001,22(7):389-394. 被引量：53
  • 9刘茂松,戴继灿.ICI治疗54例顽固性心理性ED的临床研究[J].中国现代医学杂志,2002,12(8):29-30. 被引量：3

引证文献2

二级引证文献9

中国男科学杂志
2004年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部